The Grinch had a heart that was 3 sizes too small. He delighted in the possibility that others would experience material loss. And it wasn’t until late in the Seuss tale that he discovered the true meaning of holiday cheer. With the stock market rally stalled, it seems fitting to identify ETFs that might make the mean Mr. Grinch… well… smile: 1. [...] [...more]
Amgen’s got a “Phase 3″ drug in its pipeline called, “Denosumab.” It has possibilities for a range of conditions from osteoporosis to treatment-induced bone loss to rheumatoid arthritis. Genentech has a “Phase 3″ hopeful with “Bevacizumab” (Avastin). This one’s designed to interfere with the blood supply to cancerous tumors. It is believed that if you cut off a tumor’s blood supply, you [...] [...more]
Drug distributors (pharmaceuticals) weathered the heart of the bear better than most areas. That’s not unusual for a defensive sub-segment of health care. Drug developers (biotech) have a history of volatility due to the hit-or-miss nature of creating the next big “thing’ or developing a ”flop.” Still, biotech has risk reduction qualities as a diversifier in one’s portfolio, as biotech [...] [...more]
